# KAN-HER2 MRD

Source: https://onco.cc/trials/kan-her2-mrd/  
OnCo record `kan-her2-mrd` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A small Canadian trial adding neratinib to standard treatment for women with HER2-positive breast cancer whose blood test shows leftover cancer after surgery.

## Summary

KAN-HER2 MRD (Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease, NCT05388149) adds neratinib 160 mg daily for up to 12 months to adjuvant trastuzumab emtansine in patients with residual disease detectable by the RaDaR assay. The primary endpoint is ctDNA clearance; the registry plans up to 15 participants in two stages.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Also known as: KAN-HER2
- Registry id: NCT05388149
- Phase: 2
- Setting: Resected stage I to III HER2-positive breast cancer with residual disease detectable by RaDaR after neoadjuvant therapy, surgery and the start of adjuvant trastuzumab emtansine: neratinib added
- Sponsor: University Health Network, Toronto
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT05388149: https://clinicaltrials.gov/study/NCT05388149

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Neratinib](https://onco.cc/drugs/neratinib/), [RaDaR ST](https://onco.cc/drugs/radar-mrd/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Tumour-informed versus tumour-naive ctDNA assays](https://onco.cc/terms/tumour-informed-assay/)

---
JSON: https://onco.cc/api/v1/entities/kan-her2-mrd.json